CLRB250117P1000
- 0.00
- 0.000.00%
Cellectar BioSciences Newsroom
Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development
Cellectar Biosciences Reports 83.6% Overall Response Rate for Iopofosine I 131 in Phase 2 CLOVER-WaM Study, Plans for Advancement and Regulatory Approvals
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Express News | Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $1
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Cuts Target Price to $1
Cellectar Biosciences Price Target Lowered to $1 From $7 at Maxim
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut
Cellectar Biosciences Cut to Perform From Outperform by Oppenheimer
Cellectar Biosciences Analyst Ratings
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Oppenheimer Downgrades Cellectar BioSciences(CLRB.US) to Hold Rating
Express News | Cellectar Biosciences Inc - Estimates to Incur Severance Costs of Approximately $1.7 Million
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Cellectar Stock Plunges 50% Post-market on Restructuring News
Cellectar Biosciences Trading Resumes
Cellectar Biosciences Evaluates Strategic Options for Iopofosine I 131 Amid Pipeline Focus Shift to Radiotherapeutics
Cellectar Biosciences: Anticipates Implementation of the Restructuring Will Extend Its Cash Runway Into 3Q 2025 >CLRB